Hypothesis

Transient inhibition of the histone methyltransferases SUV39H1/2 before OSKM expression lowers H3K9me3 at pericentromeric and telomeric heterochromatin, thereby increasing accessibility for reprogramming factors and decreasing the persistent methylation scars that survive iPSC generation.

Mechanistic Rationale

’s data show that incomplete reprogramming leaves megabase‑scale methylation errors concentrated at pericentromeric and telomeric regions (2). These same regions are enriched for H3K9me3, a mark that compacts chromatin and impedes transcription factor binding (6). Age‑associated cells accumulate higher levels of H3K9me3 at these loci, correlating with the observed inverse relationship between donor cell methylation load and reprogramming efficiency (1). By pharmacologically reducing SUV39H1/2 activity, we predict a local relaxation of heterochromatin, allowing OCT4, SOX2, KLF4 and c‑MYC to engage their target sites more efficiently, leading to more complete erasure of both CG and non‑CG methylation and a diminished epigenetic memory bias upon redifferentiation.

Experimental Design

1. Cell preparation – Obtain fibroblasts from young (≤20 yr) and old (>60 yr) donors. Split each line into three groups: untreated control, 24‑hour treatment with the SUV39H1/2 inhibitor chaetocin (0.5 µM), and vehicle control (DMSO).
2. Reprogramming – After inhibitor washout, induce iPSC formation using a doxycycline‑inducible OSKM system for 14 days.
3. Methylation profiling – Perform whole‑genome bisulfite sequencing on day‑14 iPSCs. Quantify residual methylation at the aberrant CpG sets identified by (0.32–1.60 % somatic, 0.57–2.98 % de novo) (2).
4. Differentiation bias assay – Differentiate iPSCs into neurons and cardiomyocytes. Measure lineage‑specific gene expression and compare to ESC‑derived controls to assess epigenetic memory (3,4).
5. Chromatin accessibility – Conduct ATAC‑seq on a subset of samples to confirm increased openness at pericentromeric/telomeric repeats after chaetocin treatment.

Predicted Outcomes

• Chaetocin‑pre‑treated cells will show a ≥30 % reduction in residual methylation at the scar loci relative to untreated iPSCs from the same donor.
• The reduction will be more pronounced in older donor cells, narrowing the efficiency gap between young and old lines.
• Differentiation derivatives from treated iPSCs will exhibit diminished bias toward the cell‑of‑origin transcriptome, approaching ESC‑like profiles.
• ATAC‑seq will reveal heightened accessibility at pericentromeric/telomeric repeats only in the chaetocin group.

Falsifiability

If chaetocin pretreatment fails to decrease residual methylation at the defined scar regions, does not improve differentiation fidelity, or does not increase chromatin accessibility at pericentromeric/telomeric sites, the hypothesis is refuted. Likewise, if the inhibitor induces cytotoxicity or aberrant pluripotency markers without affecting methylation patterns, the proposed mechanism would be insufficient to explain any observed effects.